A Single Arm, Open-label, Multicenter, Phase Ib Study of TQ05105 Tablets in Subjects With aGVHD
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Rovadicitinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 06 Aug 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2021 Planned initiation date (estimated date for recruitment of the first subject) changed to 30 Sep 2021.